Delayed hypersensitivity to 5-fluorouracil following topical chemotherapy of cutaneous cancers.
Skin tests to various common antigens, dinitrochlorobenzene, and 5-fluorouracil (5-FU) were performed on patients being treated for cutaneous neoplasms with topical 5-FU cream. Eleven of 15 patients tested both before and after therapy converted from skin test negative to positive with respect to 5-FU. This conversion correlated with positive dinitrochlorobenzene skin tests and therapeutic cure. The relation between the induction of delayed hypersensitivity reactions to 5-FU following treatment with topical 5-FU and the cure rate for cutaneous neoplasms showed a trend toward correlation.
D000287:Administration, Topical; D001706:Biopsy; D002278:Carcinoma in Situ / Q000188:drug therapy; D002280:Basal Cell Carcinoma / Q000188:drug therapy; D002281:Carcinoma, Basosquamous / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D005472:Fluorouracil / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D006968:Hypersensitivity, Delayed; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D009578:Nitrobenzenes / Q000276:immunology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D012882:Skin Tests
D007074:Immunoglobulin G; D007075:Immunoglobulin M; D009578:Nitrobenzenes; D005472:Fluorouracil